Top Stock Movers Oct 26, 2026: Why GCTK, CLRO, SGRY Surged
The biggest stock gainers at the Oct 26, 2026 close: GCTK, CLRO, SGRY, AZTR and LUCD. What moved each one, and the risks of chasing them.
GCTK — Glucotrack, Inc. (+97.2%)
Glucotrack closed up 97.2% at $1.59 on 23.9 million shares, versus a 20-day average of about 1.3 million. Its market cap is only about $4.4 million, so this is a micro-cap where a few trades can move the price a lot.
No news explains a real business change. The most relevant item is a 1-for-2 reverse stock split that took effect October 26. A reverse split cuts the share count and raises the quoted price, so the stock's per-share price can look like a jump without changing the company's value. Glucotrack also disclosed a $2 million raise through discounted convertible notes and warrants on October 22, and recent 8-Ks flag dilution. Dilution means new shares can be issued, which can weigh on existing holders.
The technical picture is weak despite the jump. RSI was 35, the moving-average stack is bearish, and the stock sits 99.3% below its 52-week high. Its relative strength rating is 1 and the conviction score is 40/100 (grade D). The squeeze score is 22/100, with a 92.8% free float and just 0.1 days to cover (how many days of average volume it would take shorts to buy back), so this is not a squeeze setup.
CLRO — CLEARONE INC (+53.2%)
ClearOne closed up 53.2% at $4.98 on about 100.7 million shares, roughly 14 times its 20-day average of 7.0 million. It opened with a gap of 33.5% (a gap is when a stock opens well above the prior close). Market cap is about $8.6 million.
Coverage pointed to speculation rather than a confirmed development. Quiver Quantitative said the stock jumped as speculators revisited the Cortigent deal despite delisting risk. The company filed an 8-K on October 13 about delisting (bearish) and another on October 15 about an agreement. Trading-focused sites described the action as a volatile, whipsawing microcap bounce.
Technically, RSI was 60 and the moving-average stack is mixed. The stock is still 69.8% below its 52-week high. The conviction score is just 8/100 (grade D). The squeeze score is 34/100, with a 32.7% free float and 0.5 days to cover. The largest disclosed stake is 61.3%, which helps explain why few shares trade freely. Low-float stocks can swing hard in both directions.
Related: Top Stock Movers Oct 23, 2026 also featured CLRO.
SGRY — Surgery Partners, Inc. (+47.6%)
Surgery Partners closed up 47.6% at $23.25 on 21.7 million shares, about 7.8 times its 20-day average of 2.8 million. This is the only large-cap-ish name here, with a market cap of about $2.1 billion.
The catalyst was a definitive merger agreement to take the company private. HealthSpan Partners, an affiliate of Bon Secours Mercy Health, agreed to buy it in an all-cash deal valued at about $5.7 billion in enterprise value. Public shareholders will receive $23.50 per share, a 49% premium to the prior close of $15.75, according to the company's press release. The companies expect to close in the first quarter of 2027, subject to shareholder and regulatory approvals. The move followed a Financial Times report on Sunday of late-stage talks at about $20 a share. RBC downgraded the stock on the deal.
Technically, the stock gapped up 46.5% and closed at a 52-week high with RSI 87, which is very overbought. Shares closed just below the $23.50 offer, which is how takeover targets typically trade. The squeeze score was 66/100, with 12.95 million shares short and 4.7 days to cover. Short sellers in a buyout face limited upside for their bets, so a classic squeeze is not the story here. Conviction is 19/100 (grade D). Insider Teresa DeLuca bought shares in August, well before the deal.
AZTR — Azitra, Inc. (+40.8%)
Azitra closed up 40.8% at $1.51 on 81.8 million shares, about 20 times its 20-day average of 4.1 million. Market cap is about $4.3 million. An intraday report had the stock up roughly 101% at one point, so much of the gain faded into the close.
The most likely catalyst is Azitra's October 26 press release on ex vivo results (tests on tissue outside the body) for its cosmetic candidate ATR-COSF. The company said it reduced the look of fine lines and wrinkles in cosmetic-surgery skin samples. A first-in-human study of 4% ATR-COSF in about 30 subjects is anticipated, with initial data expected by year end. That link is an inference from timing, as no source states the cause directly. A same-day 8-K said the company decided not to use its at-the-market offering program, but nothing ties that to the price move. A 424B5 follow-on filing in late September was bearish.
Technically, the picture is poor: RSI 36, a bearish moving-average stack, and a price 90.8% below its 52-week high. Conviction is 36/100 (grade D). The squeeze score is 24/100, with a 96.4% free float and 0.3 days to cover. A short-sale restriction is active, which limits when short sellers can act. It ranked #90 on r/pennystocks with one mention.
LUCD — Lucid Diagnostics Inc. (+23.8%)
Lucid Diagnostics closed up 23.8% at $0.51 on 77.6 million shares, about 5.5 times its 20-day average of 14.1 million. Market cap is about $83.6 million.
No news, filing or announcement explains the move. Headlines about "Lucid" mostly concern the electric-vehicle maker, a different company, so they should not be tied to this stock. The company's own recent filings were bearish: an October 22 8-K flagged dilution, and an October 16 8-K concerned delisting. The move looks momentum- and squeeze-driven.
The squeeze data is the standout. The squeeze score was 65/100, with 11.9 million shares sold short and 14.5 days to cover, a high figure. A short squeeze happens when rising prices force short sellers to buy back shares, pushing the price higher. The free float is 77.1%. The candle was a bullish belt hold, which opens at the low and rises through the day. Still, RSI was 43, the trend is bearish, and the stock is 68.8% below its 52-week high. Conviction is 40/100 (grade D). It ranked #81 on r/pennystocks with one mention.
The bottom line
Today's biggest stock gainers were a mix of a real buyout (SGRY), a reverse split (GCTK), speculation (CLRO), a press release (AZTR) and a possible squeeze (LUCD). Most are micro-caps with dilution or delisting filings, where gains often reverse quickly. Chasing extended gainers is high-risk, patterns and squeezes fail, and a buyout price caps upside. Size positions carefully, use stops, and do your own research. This is educational, not financial advice.
StockSetups scans the full US universe after every close and every premarket morning to surface movers like these. See also the premarket recap for Oct 26 and where to place a stop loss.
Frequently asked questions
Why is SGRY up today?
Surgery Partners agreed to be acquired by HealthSpan Partners, an affiliate of Bon Secours Mercy Health, for $23.50 per share in cash, about $5.7 billion in enterprise value. The stock closed up 47.6% at $23.25. Closing is expected in Q1 2027, pending approvals.
Why is GCTK up today?
Glucotrack closed up 97.2% on a 1-for-2 reverse stock split that took effect October 26. It also recently disclosed a discounted convertible note raise, which signals dilution risk. No other news explains the move.
What is a low-float short squeeze?
A low float means few shares are available to trade. If many are sold short and the price rises, short sellers may be forced to buy back, which can push the price up further. It is volatile and often reverses.
Do big one-day gainers keep rising?
Not reliably. Many small-cap spikes fade or reverse, especially those tied to dilution, delisting risk or speculation. Treat them as high-risk.
Produced with AI assistance and published under the StockSetups editorial guidelines.
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.
Start free — 14-day full access →